Endovia Health Sciences, Inc. $EDVA
Facts as of . Built from SEC filings and our own data. Small caps move fast; check the latest filings.
Snapshot
- Exchange
- NYSE American
- Sector
- Beverages
- Headquarters
- Fort Lauderdale, FL
- Fiscal year end
- December 31
- Shares outstanding
- 6,412,521 [10-Q 2026-08-19]
What the company doesAI summary of filing
Splash Beverage Group, Inc. historically specialized in manufacturing, distributing, and marketing beverages across non-alcoholic and alcoholic segments, operating a vertically integrated e-commerce platform called Qplash, and holding a wine-by-the-glass business (Copa DI Vino). The company has generated minimal revenue since February 2025 due to lack of working capital and has not generated meaningful revenue from ongoing operations, though it intends to focus on distribution of Chispo brand tequila and re-launch Qplash. The company is pre-revenue at present and has substantial doubt about its ability to continue as a going concern, funding operations through issuance of debt and equity securities rather than operating profits. [10-K 2026-04-15]
Financial health
| Period | Revenue | Net income | Operating cash flow | Cash | Filing |
|---|---|---|---|---|---|
| 6 months to Jun 2026 | $4.2K | −$4.19M | −$2.02M | $242.7K | [10-Q 2026-08-19] |
| FY ended Dec 2025 | $73.1K | −$25.23M | −$4.82M | $281.4K | [10-K 2026-04-15] |
| FY ended Dec 2024 | $801.3K | −$23.76M | −$7.30M | $13.8K | [10-K 2026-04-15] |
- Quarterly cash burn
- −$1.01M
- Cash runway Estimate
- ~0.7 months
Capital structure and dilution
| Date | Shares outstanding | Filing |
|---|---|---|
| 2025-06-30 | 1,899,876 | [10-K 2025-07-11] |
| 2025-07-11 | 1,892,471 | [10-Q 2025-07-11] |
| 2025-08-14 | 2,143,480 | [10-Q 2025-08-14] |
| 2025-11-19 | 2,550,694 | [10-Q 2025-11-19] |
| 2026-04-14 | 9,953,538 | [10-K 2026-04-15] |
| 2026-04-22 | 10,858,508 | [10-K/A 2026-04-30] |
| 2026-05-18 | 10,964,788 | [10-Q 2026-05-20] |
| 2026-08-19 | 6,412,521 | [10-Q 2026-08-19] |
- Shelf registration
- S-1 filed 2026-08-07; declared effective 2026-08-24 [S-1 2026-08-07]
Listing status
Current status: 5 Form 8-K Item 3.01 filing(s) in the last 24 months, most recent 2026-07-09. Item 3.01 covers delisting notices, failures to meet a listing rule and listing transfers; read the filing for which one.
| Date | Event | Details | Deadline | Filing |
|---|---|---|---|---|
| 2026-07-09 | 8-K Item 3.01 | Notice of delisting or failure to satisfy a continued listing rule or standard; or transfer of listing | — | [8-K 2026-07-09] |
| 2026-05-05 | 8-K Item 3.01 | Notice of delisting or failure to satisfy a continued listing rule or standard; or transfer of listing | — | [8-K 2026-05-05] |
| 2025-07-29 | 8-K Item 3.01 | Notice of delisting or failure to satisfy a continued listing rule or standard; or transfer of listing | — | [8-K 2025-07-29] |
| 2025-04-17 | 8-K Item 3.01 | Notice of delisting or failure to satisfy a continued listing rule or standard; or transfer of listing | — | [8-K 2025-04-17] |
| 2025-04-11 | 8-K Item 3.01 | Notice of delisting or failure to satisfy a continued listing rule or standard; or transfer of listing | — | [8-K 2025-04-11] |
Catalysts and calendar
| Date | Type | Title |
|---|---|---|
| 2026-10-06 | 8-K | Unregistered sale of equity |
| 2026-10-05 | DEF 14A | Proxy statement |
| 2026-10-05 | 8-K | Regulation FD disclosure |
| 2026-09-24 | 8-K | Material agreement entered; Unregistered sale of equity |
| 2026-09-23 | PRE 14A | Proxy statement |
| 2026-09-22 | 8-K | Regulation FD disclosure |
| 2026-09-18 | PRE 14A | Proxy statement |
| 2026-08-31 | 8-K | Regulation FD disclosure |
| 2026-08-28 | 8-K | Unregistered sale of equity |
| 2026-08-28 | 424B3 | Prospectus or prospectus supplement |
| 2026-08-26 | 8-K | Material agreement entered |
| 2026-08-25 | 8-K | Regulation FD disclosure |
Alerts for $EDVA
Email me when Endovia Health Sciences, Inc. files an offering, gets a deficiency notice, or moves sharply.
Facts as of . Small caps move fast; check the latest filings.